These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 26419848)
1. How to manage pasireotide, when using as medical treatment for Cushing's disease. Petersenn S Endocrine; 2015 Dec; 50(3):526-8. PubMed ID: 26419848 [No Abstract] [Full Text] [Related]
2. Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Colao A; De Block C; Gaztambide MS; Kumar S; Seufert J; Casanueva FF Pituitary; 2014 Apr; 17(2):180-6. PubMed ID: 23564338 [TBL] [Abstract][Full Text] [Related]
3. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. Silverstein JM Pituitary; 2016 Oct; 19(5):536-43. PubMed ID: 27405306 [TBL] [Abstract][Full Text] [Related]
4. Effects of anti-somatostatin agents on glucose metabolism. Vergès B Diabetes Metab; 2017 Oct; 43(5):411-415. PubMed ID: 28579289 [TBL] [Abstract][Full Text] [Related]
5. Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. Reznik Y; Bertherat J; Borson-Chazot F; Brue T; Chanson P; Cortet-Rudelli C; Delemer B; Tabarin A; Bisot-Locard S; Vergès B Diabetes Metab; 2013 Feb; 39(1):34-41. PubMed ID: 23228667 [TBL] [Abstract][Full Text] [Related]
6. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide. Pedroncelli AM Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632 [TBL] [Abstract][Full Text] [Related]
7. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial. Schopohl J; Gu F; Rubens R; Van Gaal L; Bertherat J; Ligueros-Saylan M; Trovato A; Hughes G; Salgado LR; Boscaro M; Pivonello R; Pituitary; 2015 Oct; 18(5):604-12. PubMed ID: 25537481 [TBL] [Abstract][Full Text] [Related]
14. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624 [TBL] [Abstract][Full Text] [Related]
15. Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing's disease. Cukier K; Tewari R; Kurth F; Schmid HA; Lai C; Torpy DJ Clin Endocrinol (Oxf); 2009 Aug; 71(2):305-7. PubMed ID: 19067723 [No Abstract] [Full Text] [Related]
16. Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience. Samson SL Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):445-50. PubMed ID: 25003365 [TBL] [Abstract][Full Text] [Related]
17. Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities. Truong HL; Nellesen D; Ludlam WH; Neary MP J Med Econ; 2014 Apr; 17(4):288-95. PubMed ID: 24617917 [TBL] [Abstract][Full Text] [Related]
18. The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. Simeoli C; Auriemma RS; Tortora F; De Leo M; Iacuaniello D; Cozzolino A; De Martino MC; Pivonello C; Mainolfi CG; Rossi R; Cirillo S; Colao A; Pivonello R Endocrine; 2015 Dec; 50(3):725-40. PubMed ID: 25743263 [TBL] [Abstract][Full Text] [Related]
19. Pasireotide-a novel somatostatin receptor ligand after 20 years of use. Bolanowski M; Kałużny M; Witek P; Jawiarczyk-Przybyłowska A Rev Endocr Metab Disord; 2022 Jun; 23(3):601-620. PubMed ID: 35067849 [TBL] [Abstract][Full Text] [Related]
20. Pasireotide: a review of its use in Cushing's disease. McKeage K Drugs; 2013 May; 73(6):563-74. PubMed ID: 23605695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]